At the American Diabetes Association's 86th Scientific Sessions in early June 2026, Eli Lilly reported detailed results from TRIUMPH-1 — the largest and most important trial yet for retatrutide, its investigational triple GIP/GLP-1/glucagon receptor agonist.[1] The headline numbers, first released in topline form on May 21, are the strongest weight-loss data the drug has produced.[2] But the fuller dataset also surfaced something new: a urinary tract infection signal that had not appeared in earlier retatrutide trials, occurring mostly in women.
This article walks through both sides — the efficacy that has made retatrutide the most-watched obesity drug in development, and the safety details that deserve attention before anyone calls it a finished story.
- Weight loss: 28.3% at 12 mg over 80 weeks (n=2,339), vs. 2.2% on placebo
- Sustained: up to 30.3% at 104 weeks in a higher-BMI extension group
- Sleep apnea & knee pain: large improvements in nested sub-studies
- New signal: urinary tract infections in 7.5–8.8% (treated) vs. 5.3% (placebo), mostly in women
- Status: still investigational — not FDA-approved, no NDA filed
Quick facts
- Trial name
- TRIUMPH-1
- Participants
- 2,339
- Duration
- 80 weeks (104-week extension)
- Population
- Obesity/overweight, without diabetes
- Doses tested
- 4 mg, 9 mg, 12 mg (weekly)
- Design
- Phase 3, double-blind, placebo-controlled
- Reported
- Topline May 21; ADA 2026 June 6
The efficacy story
TRIUMPH-1 enrolled 2,339 adults with obesity or overweight plus a weight-related condition, but without type 2 diabetes. At 80 weeks, mean weight loss was dose-dependent:[2]
- 4 mg: 19.0% (about 47 lb)
- 9 mg: 25.9% (about 64 lb)
- 12 mg: 28.3% (about 70 lb) vs. 2.2% (about 5 lb) on placebo
At the 12 mg dose, 45.3% of participants lost at least 30% of their body weight — a magnitude usually associated with bariatric surgery — and 65.3% reached a BMI below 30. In a pre-specified extension limited to participants who started with a BMI of 35 or higher, those who continued 12 mg reached an average of 30.3% (about 85 lb) at 104 weeks.[2]
For cross-trial context only: retatrutide's earlier TRIUMPH-4 trial showed 28.7% at 68 weeks, and semaglutide and tirzepatide have shown roughly 15% and 20–22% in their own obesity trials.[3] No head-to-head trials exist, so these comparisons are suggestive, not definitive.
Sleep apnea and knee osteoarthritis
TRIUMPH-1 embedded two "basket" sub-studies, and both reported at ADA 2026:[1]
- Obstructive sleep apnea (n=243): the apnea–hypopnea index fell by up to 36.1 events per hour — roughly a 60% reduction from a baseline around 59 events per hour. These are the first reported retatrutide sleep-apnea efficacy data.
- Knee osteoarthritis (n=574): WOMAC knee-pain scores improved by up to about 73%, the largest knee-OA dataset yet for the drug.
Both findings are most plausibly driven by the substantial weight loss reducing mechanical and metabolic load — and both come from topline conference data, not peer-reviewed publications.
The new safety signal: urinary tract infections
The detail that drew the most new attention was a urinary tract infection (UTI) signal that had not been flagged in retatrutide's earlier trials. In TRIUMPH-1, UTIs were reported in 7.5% (4 mg), 8.8% (9 mg), and 8.4% (12 mg) of treated participants, compared with 5.3% on placebo — and they occurred predominantly in women.[1]
A few things keep this in proportion. The infections were generally mild to moderate, most resolved during continued treatment, and they rarely led anyone to stop the drug. Investigators noted the signal was new, hypothesized a possible link to hydration, and said it will be monitored as more data accumulate. A smaller, dose-dependent UTI signal also appeared in the diabetes trial TRANSCEND-T2D-1 (0.7%, 1.5%, and 2.9% across doses vs. 0% on placebo).
Why it matters, calmly stated: A new signal that appears for the first time in a drug's largest trial is exactly the kind of finding regulators will want explained before approval. It is not, on the current evidence, a reason for alarm — the events were mostly mild and self-limited — but it is a reason the safety picture is not yet settled.
Dysesthesia and GI effects
ADA 2026 also gave a per-dose breakdown of dysesthesia (an altered sense of touch) in TRIUMPH-1: 5.1% (4 mg), 12.3% (9 mg), and 12.5% (12 mg), versus 0.9% on placebo.[1] That is lower than the 20.9% seen at 12 mg in TRIUMPH-4, but higher than the 2–5% reported in the diabetes trial — so the true rate across populations is still being pinned down.
Gastrointestinal side effects were consistent with the GLP-1 drug class and rose with dose, with nausea, diarrhea, and constipation the most common. Adverse-event-driven discontinuations climbed with dose, reaching 11.3% at 12 mg versus 4.9% on placebo.[2]
What this means for you
Retatrutide remains investigational. It is not FDA-approved, and as of late June 2026 no New Drug Application has been publicly confirmed as filed. It is not available by prescription or from compounding pharmacies, and products sold online as "research" retatrutide are unregulated and not equivalent to a trial drug.
What TRIUMPH-1 changes is the strength — and the texture — of the evidence. The weight-loss numbers are the highest reported for any pharmaceutical agent in obesity, and the sleep-apnea and knee-pain data broaden the story beyond the scale. At the same time, a new UTI signal and a dose-dependent dysesthesia rate are reminders that the full safety profile will come into focus only with peer-reviewed publication and the remaining TRIUMPH and TRANSCEND readouts.
For the complete evidence profile — mechanism, every trial, and the full safety assessment — see our retatrutide profile.
References
- [1]Eli Lilly and Company. “Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complications.” 2026. LinkConference abstract
Eli Lilly ADA 2026 topline release (June 6, 2026) for the TRIUMPH-1 program. Source for the per-dose UTI signal, per-dose dysesthesia rates, and the nested sleep-apnea and knee-osteoarthritis basket data. Not a peer-reviewed publication.
- [2]Eli Lilly and Company. “Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial.” 2026. LinkRCT
TRIUMPH-1 topline press release (May 21, 2026). n=2,339, 80 weeks. 28.3% mean weight loss at 12 mg; 30.3% at 104 weeks in a baseline-BMI≥35 extension. Peer-reviewed publication pending.
- [3]Eli Lilly and Company. “Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial.” 2025. LinkRCT
Topline press release for TRIUMPH-4. n=445. 28.7% weight loss at 12 mg (68 weeks). Dysesthesia signal at 20.9% (12 mg).
Stay informed
Get evidence-based peptide updates. No spam, no vendor pitches — just the research and regulatory changes that matter.
Related content
Retatrutide
Full research profile covering mechanism, all clinical trials, safety data, and evidence assessment.
NewsRetatrutide's First Late-Stage Diabetes Trial
TRANSCEND-T2D-1: A1C and weight-loss results in type 2 diabetes, with much lower dysesthesia rates.
PeptideTirzepatide
The dual GIP/GLP-1 agonist from Eli Lilly. FDA-approved for three indications. Retatrutide's closest comparator.
GuideRetatrutide Is Not Compoundable
Why legitimate retatrutide access is trial-only, and why research-use vendors are not equivalent.
Disclaimer
This article is for educational purposes only. Retatrutide is an investigational drug that is not FDA-approved and is not available by prescription. The trial results described are topline data from press releases and conference presentations, not peer-reviewed publications. This is not medical advice or an endorsement of retatrutide use. Always consult a licensed healthcare provider before making decisions about any medication or clinical trial participation.